维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="TOTHFALUSI L"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Sample sizes for designing bio- equivalence studies for high variable drugs 显示文摘	TOTHFALUSI L ENDRENYI L	2012	J Pharm Pharm Sci2012，15，1：	1
2	Regulatory and study condi- tions for the determination of bioequivalence of highly variable drugs显示文摘	ENDRENYI L TOTHFALUSI L	2009	J Pharm Pharm Sci2009，12，1：	1
3	Evaluation of bioequivalenee for highly-variable drugs with scaled average bioequivalenee 显示文摘	TOTHFALUSI L ENDRENYI L GARCIA-ARETA A	2009	Clin Pharmacokinet2009，48，11：	1
4	Evaluation of the bioequivalence of highly-variable drugs and drug products 显示文摘	TOTHFALUSI L ENDRENVI L MIDHA KK	2001	Pharm Res2001，18，6：	1
5	Regulatory conditions for the determination of bioequivalence of highly variable drugs 显示文摘	Endrenyi L Tothfalusi L	2009	J Pharm Pharmaceut Sci2009，12，1：	1
6	Sample sizes for designing bioequivalence studies for highly variable drugs 显示文摘	Tothfalusi L Endrenyi L	2012	J Pharm Pharm Sci2012，15，1：	1
7	Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulato- ry burden显示文摘	ENDRENYI L TOTHFALUSI L	2013	JPharmPharmSci2013，16，5：	1
8	Scaling or wider bioequivalence limits for highly variable drugs and for the special case of Cmax显示文摘	Tothfalusi L Endrenyi L Midha K	2003	Int J Clin Pharmacol Ther2003，41，：	1
9	Limits for the scaled average bioequivalence of highly variable drugs and drug products显示文摘	Tothfalusi L Endrenyi L	2003	Pharm Res2003，20，：	1
10	Scaling or wider bioequicalence limits for highly variable drugs and for the special case of Cmax显示文摘	Tothfalusi L Endrenyi L Midha KK	2003	lnt J Clin Pharmacol Ther2003，41，：	1
11	Limits for the scaled average bioequivalence of highly variable drugs and drug products 显示文摘	Tothfalusi L Endrenyi L	2003	Pharm Res2003，20，：	1
12	Limits for the scaled average bioequivalence of highly variable drugs and drug products 显示文摘	TOTHFALUSI L ENDRENYI L	2003	Pharm Res2003，20，3：	1
13	Evalua- tion of bioequivalence for highly-varlable drugs with scaled aver- age bioequivalence显示文摘	TOTHFALUSI L ENDRENYI L GARCfA-ARIETA A	2009	Clin Pharmacokinet2009，48，11：	1
14	Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies显示文摘	Tothfalusi L Endrenyi L	2001	Int J Clin Pharmacol Ther2001，39，4：	1
15	Long-term follow-up study with repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease显示文摘	Mally J Farkas R Tothfalusi L	2004	Brain Res Bull2004，9，：	1
16	Long-term follow-up study with repetitive transcranial magnetic stimulation in Parkinson' s disease 显示文摘	Mally J Farkas R Tothfalusi L	2004	Brain Res Bu112004，64，3：	1
17	Evaluation of bioequivalence for highly variable drugs with scaled average bio- equivalence显示文摘	TOTHFALUSI L ENDRENYIL ARIETAAG	2009	Clin Pharmacokinet2009，48，11：	1
18	Subject-by-formulation in teraction indeterminations of individual bioequivalence: bias and prevalence显示文摘	Endrenyi L Tothfalusi L	1999	Pharm Res1999，16，：	1
19	Evaluation of the bioequivalence of highly-variable drugs and drug products 显示文摘	TOTHFALUSI L ENDRENYI L MIDHA K	2001	Pharm Res2001，18，6：	1
20	Evaluation of bioequivalence for highly-variable drugs with scaled average bioequivalence 显示文摘	TOTHFALUSI L ENDRENYI L GARCIA-ARETA A	2009	Clin Pharmacokinet2009，48，11：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示